Fezz, this is a very interesting as it relates to Car-T with Yescarta and Mayo Clinic Patients. It does not mention Lenzilumab, and the patients being studied are not from the Zuma-19 Collaboration with Kite/Gilead with Lenzilumab & Yeascarta, but it is discussing the occurrence of Cytokine Release Syndrome and Neurotoxicity in response to treatment with Yescarta. Have you had a chance to read this, and if so do you have an opinion on what is being discussed?